Efficacia e tollerabilità del Levetiracetam in monoterapia in adolescenti con epilessia generalizzata idiopatica

Translated title of the contribution: Efficacy and tolerability of Levetiracetam monotherapy in adolescents with idiopathic generalized epilepsy

C. Cerminara, R. Cusmai, S. Seri, R. Bombardieri, M. Pinci, F. Vigevano, P. Curatolo

Research output: Contribution to journalArticlepeer-review

Abstract

Levetiracetam (LEV) is a pyrrolidone derivative, approved 2000 in Europe. More recent reports seem to suggest its efficacy on generalised seizures in the context of idiopathic epilepsies. The aim of our study was to report on the efficacy and the tolerability of LEV monotherapy in idiopathic generalized epilepsy in an unselected group of adolescents who attended the epilepsy services of the participating hospitals in the period Jan 2002-Dec 2003. Our experience, albeit on a small sample, seems to suggest that LEV can be extremely effective and well tolerated as monotherapy in patients generalized seizures. Our encouraging results, if confirmed by blinded studies using appropriate randomisation, suggest that LEV has the potential to be considered as first-line treatment particularly in adolescent females with JME, given the well-known potentially teratogenic effect of sodium valproate.

Translated title of the contributionEfficacy and tolerability of Levetiracetam monotherapy in adolescents with idiopathic generalized epilepsy
Original languageItalian
Pages (from-to)177-178
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number129-130
Publication statusPublished - 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy and tolerability of Levetiracetam monotherapy in adolescents with idiopathic generalized epilepsy'. Together they form a unique fingerprint.

Cite this